It seems like AspenBio Pharma (NASDAQ:APPY) is being talked about on just about every corner down Wall Street, and it’s not without merit. We first wrote a report entitled “Is AspenBio Pharma Next To Follow In The Footsteps Of Dendreon and Human Genome Sciences?” on April 21st, and since then, the share price has gained [...]

AspenBio Pharma, Inc.
(Public, NASDAQ:APPY)
AspenBio Pharma is about the embark on the most critical journey the company has ever faced since inception, with three important company developments awaiting announcements all within the next two weeks. At the forefront is the pivotal, stand alone 800 patient clinical trial result which is due in the first week of [...]

AspenBio Pharma (NASDAQ:APPY) is a biotechnology company with 2 departments, and is pending finalizing the trial results and submitting the new 510(k) for AppyScore, device for detection of acute appendicitis, in the second quarter of 2010. This clinical trial is statistically sized to stand alone and thereby becomes the pivotal trial to [...]